Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of “Moderate Buy” by Brokerages

Immuneering Corporation (NASDAQ:IMRX) has received an average recommendation of “Moderate Buy” from the seven analysts that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $16.50.

IMRX has been the subject of several analyst reports. Leerink Partners initiated coverage on shares of Immuneering in a research report on Friday, October 31st. They set an “outperform” rating and a $15.00 price target for the company. Wall Street Zen cut shares of Immuneering from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immuneering in a research report on Monday, December 29th. Chardan Capital reissued a “buy” rating and issued a $20.00 price target on shares of Immuneering in a research note on Thursday, November 13th. Finally, Mizuho set a $12.00 price objective on Immuneering in a research note on Wednesday, October 29th.

Insider Activity

In other news, Director Peter Feinberg acquired 20,000 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The stock was purchased at an average price of $4.35 per share, for a total transaction of $87,000.00. Following the completion of the acquisition, the director owned 135,441 shares in the company, valued at $589,168.35. This trade represents a 17.32% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Thomas J. Schall bought 21,645 shares of the business’s stock in a transaction on Thursday, January 15th. The stock was purchased at an average price of $4.67 per share, for a total transaction of $101,082.15. Following the completion of the acquisition, the director owned 74,530 shares of the company’s stock, valued at approximately $348,055.10. This trade represents a 40.93% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought a total of 51,819 shares of company stock valued at $234,472 over the last 90 days. Corporate insiders own 22.90% of the company’s stock.

Institutional Trading of Immuneering

Several hedge funds have recently added to or reduced their stakes in IMRX. Geode Capital Management LLC raised its position in shares of Immuneering by 2.0% during the second quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock worth $776,000 after purchasing an additional 4,458 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in Immuneering during the 3rd quarter worth approximately $35,000. Future Financial Wealth Managment LLC bought a new stake in Immuneering during the 3rd quarter worth approximately $35,000. Southport Management L.L.C. raised its holdings in Immuneering by 1.8% during the 4th quarter. Southport Management L.L.C. now owns 277,501 shares of the company’s stock worth $1,826,000 after buying an additional 5,000 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in Immuneering by 46.4% in the third quarter. Dimensional Fund Advisors LP now owns 19,562 shares of the company’s stock valued at $137,000 after buying an additional 6,196 shares in the last quarter. Institutional investors and hedge funds own 67.65% of the company’s stock.

Immuneering Stock Up 2.7%

Immuneering stock opened at $5.24 on Thursday. The business’s 50-day simple moving average is $5.39 and its 200 day simple moving average is $6.02. The stock has a market cap of $338.35 million, a price-to-earnings ratio of -2.94 and a beta of 0.46. Immuneering has a 12-month low of $1.10 and a 12-month high of $10.08.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.